Notification Date: March 5, 2024 Effective Date: April 18, 2024

# Previous Viral Hepatitis (Unknown Type), Serum

**Test ID:** PHEPU; performed at Mayo Clinic Laboratories Florida.

#### **Useful for:**

Determining if an individual has been infected following exposure to an unknown type of viral hepatitis virus. Obtaining baseline serologic markers of an individual exposed to a source with an unknown type of hepatitis. Determining immunity to hepatitis A and B viral infections

#### **Profile Information:**

Test ID	Reporting Name	Available Separately	Always Performed
HAVTA	Hepatitis A Virus Total Ab, S	Yes	Yes
HBAG	HBs Antigen, S	Yes	Yes
HBAB	HBs Antibody, S	Yes	Yes
НВС	HBc Total Ab, S	Yes	Yes
HCVDX	HCV Ab w/Reflex to HCV PCR, S	Yes	Yes

# **Reflex Tests:**

Test ID	Reporting Name	Available Separately	Always Performed
HBGNT	HBs Antigen Confirmation, S	No	No
HCVQN	HCV RNA Detect/Quant, S	Yes	No

## **Testing Algorithm:**

If hepatitis C virus (HCV) antibody is reactive, then HCV RNA detection and quantification by real-time reverse transcription polymerase chain reaction will be performed at an additional charge.

If hepatitis B virus surface antigen (HBsAg) is reactive, then HBsAg confirmation will be performed at an additional charge.

#### Methods:

HAVTA, HBAG, HBAB, HBC, HCVDX, HBGNT: Electrochemiluminescence Immunoassay (ECLIA) HCVQN: Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

#### **Reference Values:**

HEPATITIS B VIRUS SURFACE ANTIGEN Negative

HEPATITIS B VIRUS SURFACE ANTIGEN CONFIRMATION Negative

HEPATITIS B VIRUS SURFACE ANTIBODY, QUALITATIVE/QUANTITATIVE

Hepatitis B Surface Antibody Unvaccinated: Negative Vaccinated: Positive

HEPATITIS B VIRUS SURFACE ANTIBODY, QUANTITATIVE

Unvaccinated: <8.5 mIU/mL Vaccinated: > or =11.5 mIU/mL

HEPATITIS B VIRUS CORE TOTAL ANTIBODIES

Negative

HEPATITIS A VIRUS TOTAL ANTIBODY

Unvaccinated: Negative Vaccinated: Positive

HEPATITIS C VIRUS ANTIBODY

Negative

HEPATITIS C VIRUS RNA DETECTION and QUANTIFICATION by REAL-TIME RT-PCR

Undetected

# **Specimen Requirements:**

**Patient Preparation:** For 24 hours before specimen collection, patient should **not** take multivitamins or

dietary supplements (e.g. hair, skin, and nail supplements) containing biotin

(Vitamin B7)

**Supplies:** Sarstedt 5 mL Aliquot Tube (T914)

Collection Container/Tube: Serum gel
Submission Container/Tube: Plastic vial

Specimen Volume: 2.6 mL

**Collection Instructions:** 1. Centrifuge blood collection tube per manufacturer's instructions (e.g.

centrifuge and aliquot within 2 hours of collection for BD Vacutainer tubes).

2. Aliquot 1.8 mL serum into a plastic vial and ship frozen (preferred).

Minimum Volume: 1.8 mL

# **Specimen Stability Information:**

Specimen Type	Temperature	Time
Serum SST	Frozen (preferred)	84 days
	Refrigerated	6 days

#### Cautions:

Positive hepatitis B surface antigen (HBsAg) results may need to be reported by the healthcare providers to their communicable disease surveillance units of state departments of health, as required by law in various states.

Type-specific tests should be used to evaluate individuals who have been exposed to a source with a known type of hepatitis (eg, hepatitis A, hepatitis B, hepatitis C).

Serum specimens from individuals taking biotin supplements at 20 mg or more per day may have **false-positive** results for HAV total antibody and HBc total antibody, as well as **false-negative** results for HBsAg and HCV total antibody, due to interference of biotin with the assay. Such individuals should stop taking these biotin-containing dietary supplements for minimum 12 hours before blood collection for this test.

#### **CPT Code:**

86704

86706

86708

86803

87340

87341 (if appropriate)

87522 (if appropriate)

Day(s) Performed: Profile tests: Monday through Friday, Sunday; Reflex tests: Varies

Report Available: Same day/1 to 2 days

#### Questions

Contact Bonnie Meyers, Laboratory Resource Coordinator at 800-533-1710.